Table 1 Patients’ and caregivers’ characteristics
Patients (N = 128) | |
|---|---|
Sex | |
Female | n = 89 (70 %) |
Male | n = 39 (30 %) |
Age at the time of the interview | |
Median (range) | 69 years (36–88) |
Diagnoses | |
Metastatic breast cancer | n = 72 (56 %) |
Metastatic prostate cancer | n = 18 (14 %) |
Metastatic renal cell cancer | n = 9 (7 %) |
Other metastatic solid tumors | n = 29 (23 %) |
Administered oral anticancer drugs | |
Hormonal therapies | |
Letrozole | n = 17 (13 %) |
Abiraterone acetate | n = 11 (9 %) |
Exemestan | n = 11 (9 %) |
Anastrozole | n = 10 (8 %) |
Exemestane/everolimus | n = 7 (5 %) |
Other hormonal therapies | n = 13 (10 %) |
Oral chemotherapies | |
Capecitabine | n = 27 (21 %) |
Other chemotherapies | n = 7 (5 %) |
Capecitabine + hormonal therapy | n = 2 (2 %) |
Signal transduction inhibitors | |
Pazopanib | n = 7 (5 %) |
Other signal transduction inhibitors | n = 15 (12 %) |
Temozolomide + vemurafenib | n = 1 (1 %) |
Level of education | |
No educational qualification | n = 2 (2 %) |
Secondary school | n = 106 (83 %) |
A levels | n = 12 (9 %) |
University | n = 8 (6 %) |
Employment status | |
Employed | n = 16 (13 %) |
Retired | n = 99 (77 %) |
Not employed | n = 13 (10 %) |
Caregivers (N = 65) | |
Sex | |
Female | n = 39 (60 %) |
Male | n = 26 (40 %) |
Age at the time of the interview | |
Median (range) | 62 years (21–82) |
Relationship to the patient | |
Partner | n = 45 (69 %) |
Child | n = 15 (23 %) |
Other | n = 5 (8 %) |
Living in the same household | |
Yes | n = 45 (69 %) |
No | n = 20 (31 %) |